Effect of IBD medications on COVID-19 outcomes: results from an international registry.

Ryan C UngaroErica J BrennerRichard B GearryGilaad G KaplanMichele Kissous-HuntJames D LewisWilliam K K WuJean-Francois RahierWalter ReinischFlávio SteinwurzFox E UnderwoodXian ZhangJean-Frederic ColombelMichael D Kappelman

Published in: Gut (2020)

Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19. No significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.MKH should be changed to MDK for co-last author line.

Keyphrases

combination therapy
coronavirus disease
sars cov
respiratory syndrome coronavirus
early onset
adipose tissue
glycemic control